Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0FGLFW
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
ATG-022
|
|||||
| Synonyms |
ATG 022; ATG-022; ATG-022 ADC; ATG022
Click to Show/Hide
|
|||||
| Organization |
Antengene Corporation Co., Ltd.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
Undisclosed
|
|||||
| Structure |
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Claudin-18.2 (CLDN18.2)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
| Combination Type |
vedotin
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05718895 | Clinical Status | Phase 1 | ||
| Clinical Description | An open, multi-center, phase 1 clinical study of ATG 022 in patients with advanced/metastatic solid tumors. | ||||
References